25 października Unia Europejska zatwierdziła pozwolenie na wprowadzenie nowego antydepresanta.
W polskich aptekach już na wiosnę 2014.
Wklejam pełen opis, dodatkowo sporo informacji na WIKI.
About Brintellix (vortioxetine)
The mechanism of action of vortioxetine is thought to be related to its direct
modulation of serotonergic receptor activity and inhibition of the serotonin
(5-HT) transporter. Nonclinical data indicate that vortioxetine is a 5-HT3,
5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A
receptor agonist and inhibitor of the 5-HT transporter, leading to modulation
of neurotransmission in several systems, including predominantly the serotonin
but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA
and glutamate systems. This multimodal activity is considered responsible for
the antidepressant and anxiolytic-like effects and the improvement of cognitive
function, learning and memory observed with vortioxetine in animal studies.
However, the precise contribution of the individual targets to the observed
pharmacodynamic profile remains unclear and caution should be applied when
extrapolating animal data directly to man.
The World Health Organization has issued a new Anatomical Therapeutic Chemical
(ATC) code for Brintellix to be implemented in 2014.
Brintellix was discovered by Lundbeck researchers in Copenhagen, Denmark.
Brintellix received FDA approval for the treatment of major depressive disorder
on 30 September 2013.